Obesity has become a major global public health challenge. According to the World Obesity Federation, approximately 3 billion people worldwide were overweight or obese by 2024. Excess weight not only affects quality of life but also significantly increases the risk of cardiovascular disease, diabetes, sleep apnea, and other related conditions.
In recent years, weight loss medications have become an important tool in managing obesity. GLP-1 receptor agonists, such as Wegovy and Ozempic, have gained popularity, but some patients do not respond adequately to these treatments.
A recent Phase 2 clinical trial published in The Lancet brings new hope: Eloralintide, developed by Eli Lilly, targets a different hormone called amylin, and has demonstrated significant weight loss in adults with obesity or overweight.
Mechanism of Action
Eloralintide is a selective amylin receptor agonist administered via subcutaneous injection once per week. Amylin is a hormone secreted by the pancreas after meals, regulating appetite, slowing gastric emptying, and participating in energy metabolism.
Eloralintide mimics amylin’s effect, acting on the brain to control hunger while helping the body manage energy utilization, making it an effective tool for weight management.
Clinical Trial Results
The Phase 2 trial included 263 adults with obesity or overweight, all with at least one obesity-related comorbidity, and none with type 2 diabetes. After 48 weeks:
-
Participants on Eloralintide lost an average of 9%-20% of their body weight, compared to 0.4% in the placebo group.
-
About 90% of participants reduced their BMI by at least one category.
-
Weight loss was accompanied by improvements in waist circumference, blood pressure, blood sugar, lipid profiles, and inflammation markers.
These results indicate that Eloralintide not only supports weight loss but also contributes to improvements in obesity-related health indicators.
Expert Insights: Personalized Weight Management
Dr. Liana K. Billings notes that obesity is a complex chronic condition, and patients respond differently to medications. Eloralintide offers a new mechanism, providing an alternative for those who do not respond well to GLP-1 drugs, expanding personalized treatment options.
Dr. Jeffrey Kraft emphasizes that while early results are promising, long-term safety and sustainability of weight loss must be verified through Phase 3 trials, which will involve larger and more diverse populations.
Future Outlook
Eloralintide enriches the therapeutic options for obesity management, targeting a novel biological pathway. It may offer safer and more sustainable weight loss for high-risk patients. As research continues, Eloralintide could become an important tool for individualized obesity treatment while highlighting the ongoing importance of lifestyle management and comprehensive care.
Eltromin 25/50 Eltrombopag
Enatinib 4/10 Lenvatinib
Lynparib Olaparib
Coltinib Upadacitinib
Alvonib Osimertinib
Techno
Well-known pharmaceutical company in Bangladesh：https://www.radiantpharmacil.com
暂无评论内容